A group of China’s biggest pharma companies have banded together to form a Private Equity Fund that will total 1 billion RMB ($157 million). Sinopharm Capital, a subsidiary of the drug distributing giant Sinopharm, is the General Partner. Limited Partners include Sinopharm’s parent CNPGC, Fosun Pharma and China Meheco. The fund can invest in several sectors of the healthcare industry, including medical treatment, service, manufacturing, distribution, and R&D. More details.... Stock Symbols: (HK: 1099) (SHA: 600196) (SHA: 600056) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});